CD8A and neoplasm: Haratani et al. recently demonstrated that nivolumab treatment was highly effective against exon 20 T790M negative EGFR-TKI–resistant EGFR-mutant NSCLCs in cases where the EGFR-TKI–resistant tumor expressed high levels of PD-L1 together with high CD8+ TIL [15].